Commentary on “Statistics at FDA: Reflections on the Past Six Years”

References

• Alosh M., Fritsch K., Huque M., Mahjoob K., Pennello G., Rothmann M., Russek-Cohen E., Smith F., Wilson S., and Yue L. (2015), “Statistical Considerations on Subgroup Analysis in Clinical Trials” Statistics in Biopharmaceutical Research, 7, 286–303. DOI: 10.1080/19466315.2015.1077726.
   Web of Science ®Google Scholar
• ASA Biopharmaceutical Section Safety Scientific Working Group (ASA Safety WG), available at http://community.amstat.org/biop/workinggroups/safety/safety-home.
   Google Scholar
• Bretz, F., Pinheiro, J., and Branson, M. (2005) “Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies,” Biometrics, 61, 738–748. DOI: 10.1111/j.1541-0420.2005.00344.x.
   PubMed Web of Science ®Google Scholar
• DIA Missing Data Working Group, available at http://www.missingdata.org.uk/.
   Google Scholar
• DIA Adaptive Design Scientific Working Group (ADSWG). Available at https://www.phusewiki.org/wiki/index.php?title=Adaptive_Design_SWG.
   Google Scholar
• DIA Bayesian Scientific Working Group (BSWG). Available at http://www.bayesianscientific.org/.
   Google Scholar
• Duke-Margolis Center for Health Policy (2016), “Exploring Novel Statistical Methods for Rare Disease and Small Population Clinical Trials,” Durham, NC.
   Google Scholar
• Duke-Margolis Center for Health Policy (2017), “Think Tank: Exploring Novel Trial Designs and Innovative Statistical Tools in Rare Disease Drug Development,” Durham, NC.
   Google Scholar
• Duke-Margolis Center for Health Policy (2018), “Utilizing Innovative Statistical Methods and Trial Designs in Rare Disease Drug Development,” Durham, NC.
   Google Scholar
• Grosser, S., Park, M., Raney, S., and Rantou, E. (2015), “Determining Equivalence for Generic Locally Acting Drug Products,” Statistics in Biopharmaceutical Research, 7, 337–345. DOI: 10.1080/19466315.2015.1093541.
   Web of Science ®Google Scholar
• LaVange, L. M. (2014), “The Role of Statistics in Regulatory Decision Making”, Therapeutic Innovation & Regulatory Science, 48, 10–19. DOI: 10.1177/2168479013514418.
   PubMed Web of Science ®Google Scholar
• LaVange, L. M. (2019), “Statistics at FDA: Reflections on the Past Six Years”, Statistics in Biopharmaceutical Research, Submitted.
   Web of Science ®Google Scholar
• Pinheiro, J., Bornkamp, B., and Bretz, F. (2006), “Design and Analysis of Dose Finding Studies Combining Multiple Comparisons and Modeling Procedures,” Journal of Biopharmaceutical Statistics, 16, 639–656. DOI: 10.1080/10543400600860428.
   PubMed Web of Science ®Google Scholar
• Price, D., Rubin, D., and Valappil, T. (2015), “Antimicrobial Products: Statistical Challenges and Opportunities,” Statistics in Biopharmaceutical Research, 7, 325–330. DOI: 10.1080/19466315.2015.1096824.
   Web of Science ®Google Scholar
• Proschan, M.A., Dodd, L.E., and Price, D. (2016), “Statistical Considerations for a Trial of Ebola Virus Disease Therapeutics,” Clinical Trials, 13, 39–48. DOI: 10.1177/1740774515620145.
   PubMed Web of Science ®Google Scholar
• Russek-Cohen, E., Rubin, D., Price, D., Sun, W., Cox, E., and Borio, L. (2016). “A US Food and Drug Administration Perspective on Evaluating Medical Products for Ebola,”Clinical Trials, 13, 105–109. DOI: 10.1177/1740774515620613.
   PubMed Web of Science ®Google Scholar
• SCT/QSPI Working Group on Subgroup Analysis.
   Google Scholar
• Sridhara, R., He, K., Nie, L., Shen, Y.-L., and Tang S. (2015), “Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy,” Statistics in Biopharmaceutical Research, 7, 348–356. DOI: 10.1080/19466315.2015.1094673.
   Web of Science ®Google Scholar
• US Food and Drug Administration (2018a), “Complex Innovative Trial Designs Pilot Program,” Program Announcement, Silver Spring MD.
   Google Scholar
• US Food and Drug Administration (2018b), “Model-Informed Drug Development Pilot Program,” Program Announcement, Silver Spring, MD.
   Google Scholar
• US Food and Drug Administration (2018c), “Promoting the Use of Complex Innovative Designs in Clinical Trials,” Public Workshop held in Silver Spring, MD.
   Google Scholar
• US Food and Drug Administration (2016a),”Statistical Review and Evaluation Qualification of Statistical Approach”.
   Google Scholar
• Woodcock, J., and LaVange, L. M. (2017) “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both,” New England Journal of Medicine, 377, 62–70. DOI: 10.1056/NEJMra1510062.
   PubMed Web of Science ®Google Scholar